Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers.

AIDS. 1998 Jul 30;12(11):1371-80. Unique Identifier : AIDSLINE MED/98372123
Sculpher MJ; Gibb D; Ades AE; Ratcliffe J; Duong T; Health Economics Research Group, Brunel University, UK.

Abstract: OBJECTIVE: To estimate the cost of managing children with HIV/AIDS in the UK from a health service perspective. DESIGN AND METHODS: Epidemiological, resource use and unit cost data were combined within a decision analytic model. A Markov model was developed to predict the prognoses of HIV-infected children under different assumptions about natural history, treatment efficacy and the timing of antiretroviral therapy. Resource use estimates for various stages of HIV/AIDS were based on published data relating to the UK health service and clinical judgement; unit cost data were taken from a London centre. RESULTS: The base-case results suggest that the cost of caring for an HIV-infected child is higher if the mother's infection was known about at or before the child's birth (antenatal screened cohort): lifetime costs ranged from 46 427 pound sterling to 119 502 pound sterling per child in the screened cohort and from 38 691 pound sterling to 86 014 pound sterling in the unscreened cohort. However, the screened cohort benefited from longer life expectancy (base-case, 11.66 versus 10.09 years) and AIDS-free life expectancy (base-case, 7.13 years versus 6.22 years). Results are sensitive to assumptions about natural history and treatment efficacy: for example, if antiretroviral therapy was initiated at birth, and assuming optimistic natural history parameters, discounted costs could increase to 215 077 pound sterling and the additional lifetime cost of a child born to a screened mother could be 72 491 pound sterling. CONCLUSIONS: Results reflect the marked uncertainty regarding the cost of, and prognosis for, children with HIV/AIDS in the new era of more potent antiretroviral combination therapies. These results are part of an assessment of the relative cost-effectiveness of alternative antenatal HIV testing strategies.
Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/DIAGNOSIS/*ECONOMICS/ EPIDEMIOLOGY Child Comparative Study Disease Transmission, Vertical Female *Health Care Costs Human HIV Infections/DIAGNOSIS/*ECONOMICS/EPIDEMIOLOGY/TRANSMISSION Life Expectancy Markov Chains Mass Screening *Models, Economic Pregnancy *Pregnancy Complications, Infectious/DIAGNOSIS/EPIDEMIOLOGY Support, Non-U.S. Gov'tKWDjournalarticleacquiredimmunodeficiencysyndrome/diagnosis/KWDeconomics/epidemiologychildcomparativestudydiseasetransmission,verticalfemaleKWDhealthcarecostshumanhivinfections/diagnosis/KWDeconomics/epidemiology/transmissionlifeexpectancymarkovchainsmassscreeningKWDmodels,economicpregnancyKWDpregnancycomplications,infectious/diagnosis/epidemiologysupport,non-uKWDsKWDgov't
990130
A9911055

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .